Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zai LabZLAB +1.83%64 3-Year EPS without NRI Growth Rate is 23.80% as of Mar. 2026. GuruFocus rates ZLAB with a GF Score™ of 64/100 and a GF Value™ of $30.21 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,168 Biotechnology companies, Zai Lab ranks better than 59.59% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 23.80% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 18.90% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -16.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 11 years, the highest 3-Year average EPS without NRI Growth Rate of Zai Lab was 31.60% per year. The lowest was -101.00% per year. And the median was -13.65% per year.
Zai Lab (NAS:ZLAB) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Zai Lab 3-Year EPS without NRI Growth Rate Related Terms
ZLAB vs STOK, ADMA, VRDN: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Zai Lab's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zai Lab 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zai Lab's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Zai Lab's 3-Year EPS without NRI Growth Rate falls into.
Zai Lab 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 23.80% mean?
Zai Lab (ZLAB) has a 3-Year EPS without NRI Growth Rate of 23.80% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Zai Lab and its competitors. According to the industry distribution chart, Zai Lab ranks #472 out of 1168 companies in the Biotechnology industry, placing it in the top 40.4%.
Is Zai Lab's 3-Year EPS without NRI Growth Rate too high?
Zai Lab's current 3-Year EPS without NRI Growth Rate is 23.80%. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.40. Zai Lab's value of 23.80% is 45.1% above this industry median. Based on the distribution chart, Zai Lab ranks #472 out of 1168 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zai Lab has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zai Lab's 3-Year EPS without NRI Growth Rate compare to STOK and ADMA?
According to the Biotechnology industry distribution chart, Zai Lab ranks #472 out of 1168 companies for 3-Year EPS without NRI Growth Rate. This puts Zai Lab in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.40. Zai Lab's value of 23.80% is 45.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zai Lab's current 3-Year EPS without NRI Growth Rate of 23.80% is 45.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Zai Lab and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zai Lab's current 3-Year EPS without NRI Growth Rate is 23.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zai Lab stock overvalued right now?
Based on GuruFocus' analysis, Zai Lab (ZLAB) is currently considered Possible Value Trap. The stock's GF Value™ is $30.21, compared to a current price of $20.82 — trading 31.1% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 23.80% and 45.1% above the Biotechnology industry median of 16.40. Zai Lab's overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Zai Lab (ZLAB), the current 3-Year EPS without NRI Growth Rate is 23.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zai Lab (ZLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Zai Lab stock appears to be undervalued.
The current stock price of $20.82 is trading 31.1% below its estimated GF Value™ of $30.21.
GuruFocus considers Zai Lab to be Possible Value Trap.
Key valuation signals for ZLAB:
3-Year EPS without NRI Growth Rate: 23.80%
GF Value™: $30.21 vs. price of $20.82 (31.1% below fair value)
Industry Position: 45.1% above the Biotechnology median (#472 of 1168)
No single metric tells the full story. See the ZLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
64GF Score
Get the complete analysis for ZLAB
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLAB has been successfully added to your 
